Krystal Net Invested Capital from 2010 to 2024

KRYS Stock  USD 160.05  1.55  0.96%   
Krystal Biotech Net Invested Capital yearly trend continues to be comparatively stable with very little volatility. Net Invested Capital will likely drop to about 401.1 M in 2024. Net Invested Capital is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. View All Fundamentals
 
Net Invested Capital  
First Reported
2010-12-31
Previous Quarter
778.6 M
Current Value
401.1 M
Quarterly Volatility
242.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal main balance sheet or income statement drivers, such as Net Interest Income of 23.8 M, Interest Income of 23.8 M or Depreciation And Amortization of 6.2 M, as well as many exotic indicators such as Price To Sales Ratio of 72.59, Dividend Yield of 0.0 or PTB Ratio of 4.11. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
  
This module can also supplement Krystal Biotech's financial leverage analysis and stock options assessment as well as various Krystal Biotech Technical models . Check out the analysis of Krystal Biotech Correlation against competitors.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Latest Krystal Biotech's Net Invested Capital Growth Pattern

Below is the plot of the Net Invested Capital of Krystal Biotech over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Krystal Biotech's Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital10 Years Trend
Slightly volatile
   Net Invested Capital   
       Timeline  

Krystal Net Invested Capital Regression Statistics

Arithmetic Mean219,967,701
Geometric Mean123,360,817
Coefficient Of Variation110.38
Mean Deviation198,366,001
Median49,474,000
Standard Deviation242,793,808
Sample Variance58948.8T
Range729.2M
R-Value0.82
Mean Square Error20731.1T
R-Squared0.67
Significance0.0002
Slope44,552,499
Total Sum of Squares825283.7T

Krystal Net Invested Capital History

2024401.1 M
2023778.6 M
2022522.2 M
2021593.6 M
2020292.1 M
2019202.9 M
2018113.2 M

About Krystal Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Krystal Biotech income statement, its balance sheet, and the statement of cash flows. Krystal Biotech investors use historical funamental indicators, such as Krystal Biotech's Net Invested Capital, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may use each financial statement separately, they are all related. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Krystal Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Krystal Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Krystal Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Invested Capital778.6 M401.1 M

Pair Trading with Krystal Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Krystal Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Krystal Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Krystal Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Krystal Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Krystal Biotech to buy it.
The correlation of Krystal Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Krystal Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Krystal Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Krystal Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Krystal Biotech is a strong investment it is important to analyze Krystal Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Krystal Biotech's future performance. For an informed investment choice regarding Krystal Stock, refer to the following important reports:
Check out the analysis of Krystal Biotech Correlation against competitors.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Krystal Stock analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Is Krystal Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
2.18
Revenue Per Share
3.451
Return On Assets
(0.05)
Return On Equity
0.0887
The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.